RA
ALNY icon

Riversedge Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Riversedge Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-471
Closed -$215K – 215
2025
Q3 		$215K Buy
+471
New +$192K 0.04% 182

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Riversedge Advisors's ALNY Position: Q4 2025 in Review

Riversedge Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 471 shares — an estimated $215K sold.

Riversedge Advisors first reported a position in ALNY in Q3 2025 and held it in 1 quarter. The position peaked at $215K in Q3 2025. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Riversedge Advisors reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Riversedge Advisors sold 471 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $215K.
  • Riversedge Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Riversedge Advisors's Alnylam Pharmaceuticals position peaked at $215K in Q3 2025.
  • 851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Riversedge Advisors's 13F filing for Q4 2025, filed 7 Jan 2026.